English

LA JOLLA PHARMACEUTICAL CO

EDGAR

LJPC Quarterly report (10-Q) · filed 2022-08-15

237 filing records in this dataset, filed from 1996-05-15 to 2022-08-15. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

10.5 million USD

2022 Q2 · USD

Exact inputs and evidence

Revenue: 10543000 USD Source

Operating margin

-10.15%

2022 Q2 · %

Exact inputs and evidence

Operating Income: -1070000 USD Source
Revenue: 10543000 USD Source

Operating cash flow

6.7 million USD

2022 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: 9203000 USD Source
Operating Cash Flow: 2500000 USD Source

Cash and cash equivalents: 48.3 million USD 2022-06-30 Source
Exact value

48338000 USD
Long-term debt including current maturities: 124 million USD 2018-12-31 Source
Exact value

124323000 USD
Shares outstanding: 25 million shares 2022-06-30 Source
Exact value

24950487 shares

Reported share-count change

-9.21% · -2.53 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

27482231 shares · 2021-06-30· Source
24950487 shares · 2022-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

46.5 million USD

2021-07-01 – 2022-06-30

Exact inputs and evidence

Revenue: 13314000 USD · 2021-07-01 – 2021-09-30 Source
Revenue: 75720000 USD · 2021-01-01 – 2021-12-31 Source
Revenue: 63510000 USD · 2021-01-01 – 2021-09-30 Source
Revenue: 10425000 USD · 2022-01-01 – 2022-03-31 Source
Revenue: 10543000 USD · 2022-04-01 – 2022-06-30 Source

Net income

3.97 million USD

2021-07-01 – 2022-06-30

Exact inputs and evidence

Net income: -2260000 USD · 2021-07-01 – 2021-09-30 Source
Net income: 19660000 USD · 2021-01-01 – 2021-12-31 Source
Net income: 15891000 USD · 2021-01-01 – 2021-09-30 Source
Net income: 2000 USD · 2022-01-01 – 2022-03-31 Source
Net income: 2458000 USD · 2022-04-01 – 2022-06-30 Source

Operating cash flow

13.1 million USD

2021-07-01 – 2022-06-30

Exact inputs and evidence

Operating cash flow: 25080000 USD · 2021-01-01 – 2021-09-30 Source
Operating cash flow: 24314000 USD · 2021-01-01 – 2021-06-30 Source
Operating cash flow: 28244000 USD · 2021-01-01 – 2021-12-31 Source
Operating cash flow: 25080000 USD · 2021-01-01 – 2021-09-30 Source
Operating cash flow: 2500000 USD · 2022-01-01 – 2022-03-31 Source
Operating cash flow: 9203000 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: 2500000 USD · 2022-01-01 – 2022-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2022-08-15.

Financial data available through: 2021-12-31.

Coverage by financial measure

Revenue: 9 of 11 periods available· newest 2021-12-31
Operating income: 11 of 11 periods available· newest 2021-12-31
Net income: 11 of 11 periods available· newest 2021-12-31
Operating cash flow: 11 of 11 periods available· newest 2021-12-31
Capital expenditure: 9 of 11 periods available· newest 2021-12-31
Total assets: 9 of 11 periods available· newest 2021-12-31
Total liabilities: 6 of 11 periods available· newest 2021-12-31
Current assets: 9 of 11 periods available· newest 2021-12-31
Current liabilities: 9 of 11 periods available· newest 2021-12-31
Cash and cash equivalents: 9 of 11 periods available· newest 2021-12-31
Long-term debt including current maturities: 2 of 11 periods available· newest 2018-12-31
Shares outstanding: 9 of 11 periods available· newest 2021-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+126.6%

Prior period

USD 33.42 million

2020-01-01 – 2020-12-31
Current period

USD 75.72 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

75720000 − 33419000 = 42301000 USD

33419000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
75720000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · LA JOLLA PHARMACEUTICAL CO · 2021-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Year-over-year change in Revenue: 42301000 USD Concept: fundies:Revenue Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 75720000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000156459022009182/ljpc-10k_20211231.htm#1170384 Filing: 000156459022009182 Input fundies:Revenue: 33419000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000156459022009182/ljpc-10k_20211231.htm#1172157 Filing: 000156459022009182
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 59.08 million

Prior period

−USD 39.42 million

2020-01-01 – 2020-12-31
Current period

USD 19.66 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

19660000 − -39421000 = 59081000 USD

-39421000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
19660000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · LA JOLLA PHARMACEUTICAL CO · 2021-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Year-over-year change in Net income: 59081000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: 19660000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000156459022009182/ljpc-10k_20211231.htm#1466332 Filing: 000156459022009182 Input fundies:NetIncome: -39421000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000156459022009182/ljpc-10k_20211231.htm#1468042 Filing: 000156459022009182
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 65.88 million

Prior period

−USD 37.64 million

2020-01-01 – 2020-12-31
Current period

USD 28.24 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

28244000 − -37640000 = 65884000 USD

-37640000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
28244000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · LA JOLLA PHARMACEUTICAL CO · 2021-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Year-over-year change in Operating cash flow: 65884000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 28244000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000156459022009182/ljpc-10k_20211231.htm#1538685 Filing: 000156459022009182 Input fundies:OperatingCashFlow: -37640000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000156459022009182/ljpc-10k_20211231.htm#1540495 Filing: 000156459022009182
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2021 2021-01-01 – 2021-12-31

Revenue USD 75.72 million 100% of revenue
Operating costs Derived USD 53.89 million 71% of revenue
Operating income USD 21.83 million 29% of revenue
Tax, interest and other Derived USD 2.17 million 2.9% of revenue
Net income USD 19.66 million 26% of revenue

Cash

Operating cash flow USD 28.24 million 37% of revenue
Capital expenditure USD 9,000 0% of revenue
Free cash flow Derived USD 28.24 million 37% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2013 Not shown: operating income or net income is not reported.
2014 Not shown: operating income or net income is not reported.
2015 Operating loss: operating costs were 4,071% of revenue.
2016 Operating loss: operating costs were 12,823% of revenue.
2017 Not shown: operating income or net income is not reported.
2018 Operating loss: operating costs were 673% of revenue.
2019 Operating loss: operating costs were 576% of revenue.
2020 Operating loss: operating costs were 207% of revenue.
2021 26%71%

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2013 2013-01-01 – 2013-12-31	0	17941000 Derived	-17941000	-6000 Derived	-17935000	-4777000 Derived	Source 2013-01-01 – 2013-12-31: 0 USD Inspect Revenue Open source 2013-01-01 – 2013-12-31: -17941000 USD Inspect Operating Income Open source 2013-01-01 – 2013-12-31: -17935000 USD Inspect Net Income Open source 2013-01-01 – 2013-12-31: -4734000 USD Inspect Operating Cash Flow Open source 2013-01-01 – 2013-12-31: 43000 USD Inspect Capital Expenditure Open source
2014 2014-01-01 – 2014-12-31	0	21340000 Derived	-21340000	-40000 Derived	-21300000	-13137000 Derived	Source 2014-01-01 – 2014-12-31: 0 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -21340000 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -21300000 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: -12879000 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 258000 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	1057000	43026000 Derived	-41969000	-57000 Derived	-41912000	-26999000 Derived	Source 2015-01-01 – 2015-12-31: 1057000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -41969000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -41912000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -25183000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 1816000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	616000	78988000 Derived	-78372000	-187000 Derived	-78185000	-60927000 Derived	Source 2016-01-01 – 2016-12-31: 616000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -78372000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -78185000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -58709000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 2218000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	0	115427000 Derived	-115427000	-624000 Derived	-114803000	-94275000 Derived	Source 2017-01-01 – 2017-12-31: 0 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -115427000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -114803000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -85081000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 9194000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	10098000	67981000 Derived	-57883000	4218000 Derived	-62101000	-154708000 Derived	Source 2018-01-01 – 2018-12-31: 10098000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -57883000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -62101000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -152368000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 2340000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	23054000	132855000 Derived	-109801000	6707000 Derived	-116508000	-85648000 Derived	Source 2019-01-01 – 2019-12-31: 23054000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -109801000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -116508000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -84950000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 698000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	33419000	69257000 Derived	-35838000	3583000 Derived	-39421000	Unavailable	Source 2020-01-01 – 2020-12-31: 33419000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -35838000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -39421000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -37640000 USD Inspect Operating Cash Flow Open source
2021 2021-01-01 – 2021-12-31	75720000	53889000 Derived	21831000	2171000 Derived	19660000	28235000 Derived	Source 2021-01-01 – 2021-12-31: 75720000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: 21831000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: 19660000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: 28244000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 9000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 75.7M 2021

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20132013-12-31	Revenue	0	Revenue: 0 Open source
20142014-12-31	Revenue	0	Revenue: 0 Open source
20152015-12-31	Revenue	1057000	Revenue: 1057000 Open source
20162016-12-31	Revenue	616000	Revenue: 616000 Open source
20172017-12-31	Revenue	0	Revenue: 0 Open source
20182018-12-31	Revenue	10098000	Revenue: 10098000 Open source
20192019-12-31	Revenue	23054000	Revenue: 23054000 Open source
20202020-12-31	Revenue	33419000	Revenue: 33419000 Open source
20212021-12-31	Revenue	75720000	Revenue: 75720000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

126.6% 2021

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20142014-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20152015-12-31	Year over year	No prior comparable period	Revenue: 1057000 Open source Revenue: 0 Open source
20162016-12-31	Year over year	-41.7%	Revenue: 616000 Open source Revenue: 1057000 Open source
20172017-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 616000 Open source
20182018-12-31	Year over year	No prior comparable period	Revenue: 10098000 Open source Revenue: 0 Open source
20192019-12-31	Year over year	128.3%	Revenue: 23054000 Open source Revenue: 10098000 Open source
20202020-12-31	Year over year	45%	Revenue: 33419000 Open source Revenue: 23054000 Open source
20212021-12-31	Year over year	126.6%	Revenue: 75720000 Open source Revenue: 33419000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin 28.8% 2021

Net margin 26% 2021

Free cash flow margin 37.3% 2021

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Operating margin	Not reported	Operating Income: -17941000 Open source Revenue: 0 Open source
20142014-12-31	Operating margin	Not reported	Operating Income: -21340000 Open source Revenue: 0 Open source
20152015-12-31	Operating margin	-3,970.6%	Operating Income: -41969000 Open source Revenue: 1057000 Open source
20162016-12-31	Operating margin	-12,722.7%	Operating Income: -78372000 Open source Revenue: 616000 Open source
20172017-12-31	Operating margin	Not reported	Operating Income: -115427000 Open source Revenue: 0 Open source
20182018-12-31	Operating margin	-573.2%	Operating Income: -57883000 Open source Revenue: 10098000 Open source
20192019-12-31	Operating margin	-476.3%	Operating Income: -109801000 Open source Revenue: 23054000 Open source
20202020-12-31	Operating margin	-107.2%	Operating Income: -35838000 Open source Revenue: 33419000 Open source
20212021-12-31	Operating margin	28.8%	Operating Income: 21831000 Open source Revenue: 75720000 Open source
20132013-12-31	Net margin	Not reported	Net Income: -17935000 Open source Revenue: 0 Open source
20142014-12-31	Net margin	Not reported	Net Income: -21300000 Open source Revenue: 0 Open source
20152015-12-31	Net margin	-3,965.2%	Net Income: -41912000 Open source Revenue: 1057000 Open source
20162016-12-31	Net margin	-12,692.4%	Net Income: -78185000 Open source Revenue: 616000 Open source
20172017-12-31	Net margin	Not reported	Net Income: -114803000 Open source Revenue: 0 Open source
20182018-12-31	Net margin	-615%	Net Income: -62101000 Open source Revenue: 10098000 Open source
20192019-12-31	Net margin	-505.4%	Net Income: -116508000 Open source Revenue: 23054000 Open source
20202020-12-31	Net margin	-118%	Net Income: -39421000 Open source Revenue: 33419000 Open source
20212021-12-31	Net margin	26%	Net Income: 19660000 Open source Revenue: 75720000 Open source
20132013-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -4734000 Open source Capital Expenditure: 43000 Open source
20142014-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -12879000 Open source Capital Expenditure: 258000 Open source
20152015-12-31	Free cash flow margin	-2,554.3%	Revenue: 1057000 Open source Operating Cash Flow: -25183000 Open source Capital Expenditure: 1816000 Open source
20162016-12-31	Free cash flow margin	-9,890.7%	Revenue: 616000 Open source Operating Cash Flow: -58709000 Open source Capital Expenditure: 2218000 Open source
20172017-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -85081000 Open source Capital Expenditure: 9194000 Open source
20182018-12-31	Free cash flow margin	-1,532.1%	Revenue: 10098000 Open source Operating Cash Flow: -152368000 Open source Capital Expenditure: 2340000 Open source
20192019-12-31	Free cash flow margin	-371.5%	Revenue: 23054000 Open source Operating Cash Flow: -84950000 Open source Capital Expenditure: 698000 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 33419000 Open source Operating Cash Flow: -37640000 Open source
20212021-12-31	Free cash flow margin	37.3%	Revenue: 75720000 Open source Operating Cash Flow: 28244000 Open source Capital Expenditure: 9000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD 28.2M 2021

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20132013-12-31	Operating cash flow	-4734000	Operating Cash Flow: -4734000 Open source
20142014-12-31	Operating cash flow	-12879000	Operating Cash Flow: -12879000 Open source
20152015-12-31	Operating cash flow	-25183000	Operating Cash Flow: -25183000 Open source
20162016-12-31	Operating cash flow	-58709000	Operating Cash Flow: -58709000 Open source
20172017-12-31	Operating cash flow	-85081000	Operating Cash Flow: -85081000 Open source
20182018-12-31	Operating cash flow	-152368000	Operating Cash Flow: -152368000 Open source
20192019-12-31	Operating cash flow	-84950000	Operating Cash Flow: -84950000 Open source
20202020-12-31	Operating cash flow	-37640000	Operating Cash Flow: -37640000 Open source
20212021-12-31	Operating cash flow	28244000	Operating Cash Flow: 28244000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD 28.2M 2021

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20132013-12-31	Free cash flow	-4777000	Operating Cash Flow: -4734000 Open source Capital Expenditure: 43000 Open source
20142014-12-31	Free cash flow	-13137000	Operating Cash Flow: -12879000 Open source Capital Expenditure: 258000 Open source
20152015-12-31	Free cash flow	-26999000	Operating Cash Flow: -25183000 Open source Capital Expenditure: 1816000 Open source
20162016-12-31	Free cash flow	-60927000	Operating Cash Flow: -58709000 Open source Capital Expenditure: 2218000 Open source
20172017-12-31	Free cash flow	-94275000	Operating Cash Flow: -85081000 Open source Capital Expenditure: 9194000 Open source
20182018-12-31	Free cash flow	-154708000	Operating Cash Flow: -152368000 Open source Capital Expenditure: 2340000 Open source
20192019-12-31	Free cash flow	-85648000	Operating Cash Flow: -84950000 Open source Capital Expenditure: 698000 Open source
20202020-12-31	Free cash flow	Unavailable	Operating Cash Flow: -37640000 Open source
20212021-12-31	Free cash flow	28235000	Operating Cash Flow: 28244000 Open source Capital Expenditure: 9000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

165.9% 2021

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2013-12-31	Liabilities / assets	Not reported	Total Assets: 8747000 Open source
2014-12-31	Liabilities / assets	Not reported	Total Assets: 50536000 Open source
2015-12-31	Liabilities / assets	Not reported	Total Assets: 129347000 Open source
20162016-12-31	Liabilities / assets	13.8%	Total Liabilities: 9758000 Open source Total Assets: 70795000 Open source
20172017-12-31	Liabilities / assets	26.2%	Total Liabilities: 31337000 Open source Total Assets: 119539000 Open source
20182018-12-31	Liabilities / assets	82.4%	Total Liabilities: 168371000 Open source Total Assets: 204292000 Open source
20192019-12-31	Liabilities / assets	142.3%	Total Liabilities: 188237000 Open source Total Assets: 132247000 Open source
20202020-12-31	Liabilities / assets	221.9%	Total Liabilities: 160330000 Open source Total Assets: 72243000 Open source
20212021-12-31	Liabilities / assets	165.9%	Total Liabilities: 167968000 Open source Total Assets: 101230000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

3.82× 2021

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Current assets / current liabilities	7.96×	Current Assets: 8709000 Open source Current Liabilities: 1094000 Open source
20142014-12-31	Current assets / current liabilities	24.16×	Current Assets: 50257000 Open source Current Liabilities: 2080000 Open source
20152015-12-31	Current assets / current liabilities	26.46×	Current Assets: 127545000 Open source Current Liabilities: 4820000 Open source
20162016-12-31	Current assets / current liabilities	6.91×	Current Assets: 67431000 Open source Current Liabilities: 9758000 Open source
20172017-12-31	Current assets / current liabilities	5.07×	Current Assets: 94062000 Open source Current Liabilities: 18552000 Open source
20182018-12-31	Current assets / current liabilities	6.98×	Current Assets: 181116000 Open source Current Liabilities: 25936000 Open source
20192019-12-31	Current assets / current liabilities	3.96×	Current Assets: 97458000 Open source Current Liabilities: 24587000 Open source
20202020-12-31	Current assets / current liabilities	2.95×	Current Assets: 36456000 Open source Current Liabilities: 12338000 Open source
20212021-12-31	Current assets / current liabilities	3.82×	Current Assets: 67315000 Open source Current Liabilities: 17635000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2012 2012-01-01 – 2012-12-31	−USD 7.74 million Exact value Exact value: -7737000 USD 2012-01-01 – 2012-12-31: -7737000 USD Inspect Net Income Open source Share or cite Citation for Net Income · LA JOLLA PHARMACEUTICAL CO · 2012-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Net Income: -7737000 USD Concept: fundies:NetIncome Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465/explain?concept=fundies%3ANetIncome&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:NetIncome: -7737000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046514000021/ljpc-20131231.xml#243496 Filing: 000092046514000021 The citation records this snapshot. The page link may show a newer release later.	−USD 2.14 million Exact value Exact value: -2135000 USD 2012-01-01 – 2012-12-31: -2135000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · LA JOLLA PHARMACEUTICAL CO · 2012-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Operating Cash Flow: -2135000 USD Concept: fundies:OperatingCashFlow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465/explain?concept=fundies%3AOperatingCashFlow&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -2135000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046514000021/ljpc-20131231.xml#242917 Filing: 000092046514000021 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2012-01-01 – 2012-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · LA JOLLA PHARMACEUTICAL CO · 2012-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465/explain?concept=fundies%3ACapitalExpenditure&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046514000021/ljpc-20131231.xml#318362 Filing: 000092046514000021 The citation records this snapshot. The page link may show a newer release later.	−USD 2.14 million Calculation and evidence -2135000 − 0 USD Exact free cash flow: -2135000 USD 2012-01-01 – 2012-12-31: -2135000 USD · Inspect Operating Cash Flow · Source 2012-01-01 – 2012-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · LA JOLLA PHARMACEUTICAL CO · 2012-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Free cash flow: -2135000 USD Concept: free-cash-flow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -2135000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046514000021/ljpc-20131231.xml#242917 Filing: 000092046514000021 Input fundies:CapitalExpenditure: 0 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046514000021/ljpc-20131231.xml#318362 Filing: 000092046514000021 The citation records this snapshot. The page link may show a newer release later.
2013 2013-01-01 – 2013-12-31	−USD 17.94 million Exact value Exact value: -17935000 USD 2013-01-01 – 2013-12-31: -17935000 USD Inspect Net Income Open source Share or cite Citation for Net Income · LA JOLLA PHARMACEUTICAL CO · 2013-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Net Income: -17935000 USD Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:NetIncome: -17935000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046516000106/ljpc-20151231.xml#188203 Filing: 000092046516000106 The citation records this snapshot. The page link may show a newer release later.	−USD 4.73 million Exact value Exact value: -4734000 USD 2013-01-01 – 2013-12-31: -4734000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · LA JOLLA PHARMACEUTICAL CO · 2013-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Operating Cash Flow: -4734000 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4734000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046516000106/ljpc-20151231.xml#187568 Filing: 000092046516000106 The citation records this snapshot. The page link may show a newer release later.	USD 43,000 Exact value Exact value: 43000 USD 2013-01-01 – 2013-12-31: 43000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · LA JOLLA PHARMACEUTICAL CO · 2013-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Capital Expenditure: 43000 USD Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 43000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046516000106/ljpc-20151231.xml#197564 Filing: 000092046516000106 The citation records this snapshot. The page link may show a newer release later.	−USD 4.78 million Calculation and evidence -4734000 − 43000 USD Exact free cash flow: -4777000 USD 2013-01-01 – 2013-12-31: -4734000 USD · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 43000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · LA JOLLA PHARMACEUTICAL CO · 2013-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Free cash flow: -4777000 USD Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -4734000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046516000106/ljpc-20151231.xml#187568 Filing: 000092046516000106 Input fundies:CapitalExpenditure: 43000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046516000106/ljpc-20151231.xml#197564 Filing: 000092046516000106 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	−USD 21.3 million Exact value Exact value: -21300000 USD 2014-01-01 – 2014-12-31: -21300000 USD Inspect Net Income Open source Share or cite Citation for Net Income · LA JOLLA PHARMACEUTICAL CO · 2014-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Net Income: -21300000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -21300000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046517000025/ljpc-20161231.xml#177396 Filing: 000092046517000025 The citation records this snapshot. The page link may show a newer release later.	−USD 12.88 million Exact value Exact value: -12879000 USD 2014-01-01 – 2014-12-31: -12879000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · LA JOLLA PHARMACEUTICAL CO · 2014-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Operating Cash Flow: -12879000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12879000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046517000025/ljpc-20161231.xml#176606 Filing: 000092046517000025 The citation records this snapshot. The page link may show a newer release later.	USD 258,000 Exact value Exact value: 258000 USD 2014-01-01 – 2014-12-31: 258000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · LA JOLLA PHARMACEUTICAL CO · 2014-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Capital Expenditure: 258000 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 258000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046517000025/ljpc-20161231.xml#185908 Filing: 000092046517000025 The citation records this snapshot. The page link may show a newer release later.	−USD 13.14 million Calculation and evidence -12879000 − 258000 USD Exact free cash flow: -13137000 USD 2014-01-01 – 2014-12-31: -12879000 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 258000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · LA JOLLA PHARMACEUTICAL CO · 2014-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Free cash flow: -13137000 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -12879000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046517000025/ljpc-20161231.xml#176606 Filing: 000092046517000025 Input fundies:CapitalExpenditure: 258000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046517000025/ljpc-20161231.xml#185908 Filing: 000092046517000025 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 41.91 million Exact value Exact value: -41912000 USD 2015-01-01 – 2015-12-31: -41912000 USD Inspect Net Income Open source Share or cite Citation for Net Income · LA JOLLA PHARMACEUTICAL CO · 2015-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Net Income: -41912000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -41912000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046518000007/ljpc-20171231.xml#171726 Filing: 000092046518000007 The citation records this snapshot. The page link may show a newer release later.	−USD 25.18 million Exact value Exact value: -25183000 USD 2015-01-01 – 2015-12-31: -25183000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · LA JOLLA PHARMACEUTICAL CO · 2015-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Operating Cash Flow: -25183000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -25183000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046518000007/ljpc-20171231.xml#171090 Filing: 000092046518000007 The citation records this snapshot. The page link may show a newer release later.	USD 1.82 million Exact value Exact value: 1816000 USD 2015-01-01 – 2015-12-31: 1816000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · LA JOLLA PHARMACEUTICAL CO · 2015-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Capital Expenditure: 1816000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1816000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046518000007/ljpc-20171231.xml#179977 Filing: 000092046518000007 The citation records this snapshot. The page link may show a newer release later.	−USD 27 million Calculation and evidence -25183000 − 1816000 USD Exact free cash flow: -26999000 USD 2015-01-01 – 2015-12-31: -25183000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 1816000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · LA JOLLA PHARMACEUTICAL CO · 2015-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Free cash flow: -26999000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -25183000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046518000007/ljpc-20171231.xml#171090 Filing: 000092046518000007 Input fundies:CapitalExpenditure: 1816000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046518000007/ljpc-20171231.xml#179977 Filing: 000092046518000007 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 78.19 million Exact value Exact value: -78185000 USD 2016-01-01 – 2016-12-31: -78185000 USD Inspect Net Income Open source Share or cite Citation for Net Income · LA JOLLA PHARMACEUTICAL CO · 2016-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Net Income: -78185000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -78185000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046519000044/ljpc-20181231.xml#166567 Filing: 000092046519000044 The citation records this snapshot. The page link may show a newer release later.	−USD 58.71 million Exact value Exact value: -58709000 USD 2016-01-01 – 2016-12-31: -58709000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · LA JOLLA PHARMACEUTICAL CO · 2016-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Operating Cash Flow: -58709000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -58709000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046519000044/ljpc-20181231.xml#165930 Filing: 000092046519000044 The citation records this snapshot. The page link may show a newer release later.	USD 2.22 million Exact value Exact value: 2218000 USD 2016-01-01 – 2016-12-31: 2218000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · LA JOLLA PHARMACEUTICAL CO · 2016-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Capital Expenditure: 2218000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2218000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046519000044/ljpc-20181231.xml#172172 Filing: 000092046519000044 The citation records this snapshot. The page link may show a newer release later.	−USD 60.93 million Calculation and evidence -58709000 − 2218000 USD Exact free cash flow: -60927000 USD 2016-01-01 – 2016-12-31: -58709000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 2218000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · LA JOLLA PHARMACEUTICAL CO · 2016-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Free cash flow: -60927000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -58709000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046519000044/ljpc-20181231.xml#165930 Filing: 000092046519000044 Input fundies:CapitalExpenditure: 2218000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046519000044/ljpc-20181231.xml#172172 Filing: 000092046519000044 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 114.8 million Exact value Exact value: -114803000 USD 2017-01-01 – 2017-12-31: -114803000 USD Inspect Net Income Open source Share or cite Citation for Net Income · LA JOLLA PHARMACEUTICAL CO · 2017-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Net Income: -114803000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -114803000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046519000044/ljpc-20181231.xml#166944 Filing: 000092046519000044 The citation records this snapshot. The page link may show a newer release later.	−USD 85.08 million Exact value Exact value: -85081000 USD 2017-01-01 – 2017-12-31: -85081000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · LA JOLLA PHARMACEUTICAL CO · 2017-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Operating Cash Flow: -85081000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -85081000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046519000044/ljpc-20181231.xml#166142 Filing: 000092046519000044 The citation records this snapshot. The page link may show a newer release later.	USD 9.19 million Exact value Exact value: 9194000 USD 2017-01-01 – 2017-12-31: 9194000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · LA JOLLA PHARMACEUTICAL CO · 2017-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Capital Expenditure: 9194000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9194000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046519000044/ljpc-20181231.xml#172382 Filing: 000092046519000044 The citation records this snapshot. The page link may show a newer release later.	−USD 94.28 million Calculation and evidence -85081000 − 9194000 USD Exact free cash flow: -94275000 USD 2017-01-01 – 2017-12-31: -85081000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 9194000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · LA JOLLA PHARMACEUTICAL CO · 2017-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Free cash flow: -94275000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -85081000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046519000044/ljpc-20181231.xml#166142 Filing: 000092046519000044 Input fundies:CapitalExpenditure: 9194000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046519000044/ljpc-20181231.xml#172382 Filing: 000092046519000044 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 62.1 million Exact value Exact value: -62101000 USD 2018-01-01 – 2018-12-31: -62101000 USD Inspect Net Income Open source Share or cite Citation for Net Income · LA JOLLA PHARMACEUTICAL CO · 2018-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Net Income: -62101000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -62101000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046520000127/ljpc-2020q210xq.htm#269109 Filing: 000092046520000127 The citation records this snapshot. The page link may show a newer release later.	−USD 152.37 million Exact value Exact value: -152368000 USD 2018-01-01 – 2018-12-31: -152368000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · LA JOLLA PHARMACEUTICAL CO · 2018-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Operating Cash Flow: -152368000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -152368000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046520000036/ljpc-20191231.xml#139279 Filing: 000092046520000036 The citation records this snapshot. The page link may show a newer release later.	USD 2.34 million Exact value Exact value: 2340000 USD 2018-01-01 – 2018-12-31: 2340000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · LA JOLLA PHARMACEUTICAL CO · 2018-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Capital Expenditure: 2340000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2340000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046520000036/ljpc-20191231.xml#145595 Filing: 000092046520000036 The citation records this snapshot. The page link may show a newer release later.	−USD 154.71 million Calculation and evidence -152368000 − 2340000 USD Exact free cash flow: -154708000 USD 2018-01-01 – 2018-12-31: -152368000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 2340000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · LA JOLLA PHARMACEUTICAL CO · 2018-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Free cash flow: -154708000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -152368000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046520000036/ljpc-20191231.xml#139279 Filing: 000092046520000036 Input fundies:CapitalExpenditure: 2340000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000092046520000036/ljpc-20191231.xml#145595 Filing: 000092046520000036 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 116.51 million Exact value Exact value: -116508000 USD 2019-01-01 – 2019-12-31: -116508000 USD Inspect Net Income Open source Share or cite Citation for Net Income · LA JOLLA PHARMACEUTICAL CO · 2019-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Net Income: -116508000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -116508000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000156459021011366/ljpc-10k_20201231.htm#1412121 Filing: 000156459021011366 The citation records this snapshot. The page link may show a newer release later.	−USD 84.95 million Exact value Exact value: -84950000 USD 2019-01-01 – 2019-12-31: -84950000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · LA JOLLA PHARMACEUTICAL CO · 2019-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Operating Cash Flow: -84950000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -84950000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000156459021011366/ljpc-10k_20201231.htm#1484086 Filing: 000156459021011366 The citation records this snapshot. The page link may show a newer release later.	USD 698,000 Exact value Exact value: 698000 USD 2019-01-01 – 2019-12-31: 698000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · LA JOLLA PHARMACEUTICAL CO · 2019-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Capital Expenditure: 698000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 698000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000156459021011366/ljpc-10k_20201231.htm#1498528 Filing: 000156459021011366 The citation records this snapshot. The page link may show a newer release later.	−USD 85.65 million Calculation and evidence -84950000 − 698000 USD Exact free cash flow: -85648000 USD 2019-01-01 – 2019-12-31: -84950000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 698000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · LA JOLLA PHARMACEUTICAL CO · 2019-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Free cash flow: -85648000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -84950000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000156459021011366/ljpc-10k_20201231.htm#1484086 Filing: 000156459021011366 Input fundies:CapitalExpenditure: 698000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000156459021011366/ljpc-10k_20201231.htm#1498528 Filing: 000156459021011366 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 39.42 million Exact value Exact value: -39421000 USD 2020-01-01 – 2020-12-31: -39421000 USD Inspect Net Income Open source Share or cite Citation for Net Income · LA JOLLA PHARMACEUTICAL CO · 2020-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Net Income: -39421000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -39421000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000156459022009182/ljpc-10k_20211231.htm#1468042 Filing: 000156459022009182 The citation records this snapshot. The page link may show a newer release later.	−USD 37.64 million Exact value Exact value: -37640000 USD 2020-01-01 – 2020-12-31: -37640000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · LA JOLLA PHARMACEUTICAL CO · 2020-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Operating Cash Flow: -37640000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -37640000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000156459022009182/ljpc-10k_20211231.htm#1540495 Filing: 000156459022009182 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2021 2021-01-01 – 2021-12-31	USD 19.66 million Exact value Exact value: 19660000 USD 2021-01-01 – 2021-12-31: 19660000 USD Inspect Net Income Open source Share or cite Citation for Net Income · LA JOLLA PHARMACEUTICAL CO · 2021-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Net Income: 19660000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: 19660000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000156459022009182/ljpc-10k_20211231.htm#1466332 Filing: 000156459022009182 The citation records this snapshot. The page link may show a newer release later.	USD 28.24 million Exact value Exact value: 28244000 USD 2021-01-01 – 2021-12-31: 28244000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · LA JOLLA PHARMACEUTICAL CO · 2021-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Operating Cash Flow: 28244000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 28244000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000156459022009182/ljpc-10k_20211231.htm#1538685 Filing: 000156459022009182 The citation records this snapshot. The page link may show a newer release later.	USD 9,000 Exact value Exact value: 9000 USD 2021-01-01 – 2021-12-31: 9000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · LA JOLLA PHARMACEUTICAL CO · 2021-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Capital Expenditure: 9000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000156459022009182/ljpc-10k_20211231.htm#1553485 Filing: 000156459022009182 The citation records this snapshot. The page link may show a newer release later.	USD 28.24 million Calculation and evidence 28244000 − 9000 USD Exact free cash flow: 28235000 USD 2021-01-01 – 2021-12-31: 28244000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 9000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · LA JOLLA PHARMACEUTICAL CO · 2021-12-31 LA JOLLA PHARMACEUTICAL CO (edgar:920465) Free cash flow: 28235000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:50:14Z Snapshot: 4b67f55f0a0db567b62fca8c0f4486e94c8a75c2756c2cfe55f5ad02470eacec Dimensions: Consolidated View: https://fundies.io/companies/edgar/920465?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 28244000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000156459022009182/ljpc-10k_20211231.htm#1538685 Filing: 000156459022009182 Input fundies:CapitalExpenditure: 9000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/920465/000156459022009182/ljpc-10k_20211231.htm#1553485 Filing: 000156459022009182 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

237 filings · 2,523 latest values · 2,523 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000920465, 920465, LJPC, edgar:920465

Also known as LA JOLLA PHARMACEUTICAL CO, LA JOLLA PHARMACEUTICAL COMPANY

LA JOLLA PHARMACEUTICAL CO

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Where revenue goes

2021 2021-01-01 – 2021-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation